4,923 results match your criteria Biology of Blood and Marrow Transplantation[Journal]


Outcomes and Challenges of Reproductive Health in Hematopoietic Stem Cell Transplantation Survivors.

Biol Blood Marrow Transplant 2020 Jul 10. Epub 2020 Jul 10.

Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Background: Long-term therapy-related reproductive health side effects impact quality of life of hematopoietic stem cell transplant (HSCT) survivors. Our aim was to evaluate prevalence of gonadal dysfunction (GD) pre- and post- HSCT, analyze factors associated with GD, and rates of fertility assessment (FA) and preservation (FP) in a resource-limited setting.

Methods: FA and outcomes of patients ≤45 years-old, undergoing HSCT from June 2000 to May 2018 were retrospectively collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.007DOI Listing

Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression.

Biol Blood Marrow Transplant 2020 Jul 10. Epub 2020 Jul 10.

Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea. Electronic address:

Relapse is a major concern with reduced-intensity conditioning. We analyzed 257 acute myeloid leukemia (AML) patients who received allogeneic stem cell transplantation (SCT) and fulfilled the following criteria: intermediate or poor-risk disease by NCCN guidelines (2017.Version 3), in first complete remission (CR1) at SCT, received either myeloablative conditioning (MAC; BuCy or CyTBI) or reduced-intensity conditioning (RIC; FluBu2TBI400) peripheral blood SCT from 8/8 matched sibling or unrelated donor, and having bone marrow Wilms' tumour gene 1 (WT1) expression results before transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.006DOI Listing

Histopathological Grading of Oral Mucosal Chronic Graft-versus-Host Disease: Large Cohort Analysis.

Biol Blood Marrow Transplant 2020 Jul 10. Epub 2020 Jul 10.

Division of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address:

Graft-versus-host disease (GVHD) can manifest as acute (a) or chronic(c) complications in patients post-hematopoietic cell transplantation (HCT). Oral cGVHD arises in about 70% of patients, and includes lichenoid-like mucosal reactions, restricted mouth opening and salivary gland dysfunction. However, the underlying histopathological presentation remains to be validated in large cohorts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.031DOI Listing

Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation.

Biol Blood Marrow Transplant 2020 Jul 9. Epub 2020 Jul 9.

Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milano, Italy.

Refractory/early relapsed and 17p deletion/p53 mutation (del(17p)/TP53mut)-positive chronic lymphocytic leukemia (CLL) has been conventionally considered a high-risk disease, potentially eligible for allogeneic stem cell transplantation (alloSCT). In this multicenter retrospective analysis of 157 patients, we compared the outcomes of high-risk CLL treated with alloSCT or B-cell receptor pathway inhibitors (BCRis) or both. Seventy-one patients were treated with BCRis, 67 patients underwent reduced intensity alloSCT, and 19 received alloSCT with BCRis before and/or after transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.032DOI Listing

Busulfan Pharmacokinetics in ADA SCID Gene Therapy.

Biol Blood Marrow Transplant 2020 Jul 9. Epub 2020 Jul 9.

Department of Pediatric Hematology-Oncology, University of California, Los Angeles (UCLA); Department of Microbiology, Immunology and Molecular Genetics, UCLA; Department of Molecular & Medical Pharmacology, UCLA; The Eli & Edythe Broad Stem Cell Research Center, UCLA. Electronic address:

The pharmacokinetics of low dose busulfan (BU) were investigated as a non-myeloablative conditioning regimen for autologous gene therapy (GT) in pediatric subjects with adenosine deaminase-deficient severe combined immunodeficiency (ADA SCID). In three successive clinical trials, which included either γ-retroviral (γ-RV) or lentiviral (LV) vectors, subjects were conditioned with BU using different dosing nomograms; the first cohort received BU doses based on body surface area (BSA), the second based on actual body weight (ABW), and the third utilized therapeutic drug monitoring (TDM) to target a specific area under the concentration-time curve (AUC). Neither BSA nor ABW-based dosing achieved consistent cumulative BU AUC; in contrast, use of TDM-based dosing led to more consistent AUC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.004DOI Listing

Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Biol Blood Marrow Transplant 2020 Jul 9. Epub 2020 Jul 9.

Division of Clinical Research, Fred Hutchinson Cancer Research Center; Department of Medicine, University of Washington, Seattle WA.

Bone health disturbances occur commonly after hematopoietic cell transplantation (HCT) with loss of bone mineral density (BMD) and avascular necrosis (AVN) being foremost. BMD loss is related to pre-transplant chemotherapy and radiation exposures, immunosuppressive therapy for graft-versus-host-disease (GVHD), and results from deficiencies in growth or gonadal hormones, disturbances in calcium and vitamin D homeostasis, as well as osteoblast and osteoclast dysfunction. While the pathophysiology of AVN remains unclear, high-dose glucocorticoid exposure is the most frequent association. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.001DOI Listing

Letermovir Prophylaxis Decreases Burden of CMV in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant.

Biol Blood Marrow Transplant 2020 Jul 9. Epub 2020 Jul 9.

Division of Blood and Marrow Transplantation; Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA. Electronic address:

Despite effective therapies, CMV continues to have a significant impact on morbidity and mortality in hematopoietic cell transplant recipients. At particular risk are recipients of alternative grafts such as umbilical cord blood (UCB), haploidentical transplants (haplo), or patients conditioned with T-cell depleting regimens such as anti-thymocyte globulin (ATG). With the approval of letermovir, its impact on high risk patients is of particular interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.002DOI Listing

Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation.

Biol Blood Marrow Transplant 2020 Jul 9. Epub 2020 Jul 9.

Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Blood and Marrow Transplant & Cellular Therapy Program, Froedtert & Medical College of Wisconsin, Milwaukee, WI; Center for International Blood and Marrow Transplant Research, Milwaukee Campus, Milwaukee, WI. Electronic address:

Chronic graft-versus-host disease (cGVHD) is major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Ixazomib is an oral, second-generation, proteasome inhibitor (PI) that has been shown in preclinical models to prevent GVHD. We conducted a phase I/II trial in 57 subjects to evaluate the safety and efficacy of ixazomib administration for cGVHD prophylaxis in patients undergoing allogeneic HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.005DOI Listing

Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases.

Biol Blood Marrow Transplant 2020 Jul 9. Epub 2020 Jul 9.

Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil; Hospital Nossa Senhora das Graças, Curitiba, Brazil; Hospital Infantil Pequeno Príncipe, Curitiba, Brazil.

Allogeneic hematopoietic stem cell transplantation(HCT) can cure primary immunodeficiency diseases(PID). When a HLA-matched donor is not available haploidentical family donor may be considered. The use of T-cell replete haploidentical HCT with post-transplant cyclophosphamide(Haplo-PTCy) in children with PID has been described in few case-series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.07.003DOI Listing

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

Biol Blood Marrow Transplant 2020 Jul 7. Epub 2020 Jul 7.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Electronic address:

While hematopoietic cell transplant from an HLA-matched unrelated donor is potentially curative for hematologic malignancy, survival is lower for African Americans compared to Caucasians. As only about 20% of African Americans will have an HLA-matched unrelated donor many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. Thus, the current analyses studied transplant-outcomes after HLA-haploidentical relative (n=249) and umbilical cord blood (n=118) transplants for African Americans with hematologic malignancy between 2008 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.029DOI Listing

The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT.

Biol Blood Marrow Transplant 2020 Jul 6. Epub 2020 Jul 6.

Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint-Antoine (CRSA), Paris, France; EBMT Paris study office, Paris, France.

Timing of immunosuppressive-drugs therapy used in combination with post-transplant cyclophosphamide (PTCY) in haploidentical hematopoietic stem cell transplant (Haplo-HSCT) is not standardized. We evaluated the schedule of immunosuppression therapy after haplo-HSCT in 509 patients with acute leukemia receiving PTCY on day +3 and +4 along with tacrolimus (group 1, n=215) or cyclosporine A (CSA) and mycophenolate -mofetil (MMF) from day+5 (group 2, n=170) or CSA+MMF from day 0 or 1 with PTCY on day +3 and +5 (group 3, n=124). Patients in group 3 were younger (median age 46 years, p=0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.026DOI Listing

Unrelated donor transplant recipients given Thymoglobuline have superior GRFS when compared to matched related donor recipients transplanted without ATG.

Biol Blood Marrow Transplant 2020 Jul 5. Epub 2020 Jul 5.

Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, 2050, Australia; Westmead Hospital, Hawkesbury Rd, Westmead, NSW, 2145, Australia.

Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated (URD) and mismatched related donors (MMRD) typically have a higher incidence of acute and chronic graft-versus-host disease (GVHD) compared to matched related donors (MRD). Anti-T-cell globulins (ATG) are often used to reduce GVHD in these recipients. We report the outcomes of 211 adult peripheral blood stem cell transplant recipients with myeloid malignancies who received a standardized transplant protocol, in which ATG (Thymoglobuline 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.030DOI Listing
July 2020
3.404 Impact Factor

Impact of preemptive therapy for Cytomegalovirus on hospitalizations and cost after Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2020 Jul 5. Epub 2020 Jul 5.

Memorial Sloan Kettering Cancer Center, Infectious Disease Service, New York, NY, United States; Weill Cornell Medical College, Cornell University, New York, NY, United States. Electronic address:

Background: CMV viremia occurs in 40%-80% of CMV seropositive (R+) allogeneic hematopoietic stem cell (HCT) recipients. The preemptive therapy (PET) strategy has reduced the risk of CMV end-organ disease (EOD) and associated mortality but may lead to substantial healthcare resource utilization (HCRU) and cost. Real-world data on the economic impact of PET is relevant for the evaluation of alternative strategies for CMV management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.025DOI Listing

Predicting mortality after autologous transplant: Development of a novel risk score.

Biol Blood Marrow Transplant 2020 Jul 5. Epub 2020 Jul 5.

Hematology Transplant Unit, Hospital Universitario Austral, Derqui, Argentina.

There have been several efforts to predict mortality after autologous stem cell transplantation (ASCT), such as the Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI), described for allogeneic-SCT and validated for ASCT, however there is no composite score in the setting of ASCT combining comorbidities with other clinical characteristics. Our aim is to describe a comprehensive score combining comorbidities with other clinical factors and to analyze the impact of this score on non-relapse mortality (NRM), overall survival (OS) and early morbidity end-points (mechanical ventilation, shock or dialysis) after ASCT. For the training cohort, we retrospectively reviewed data of 2068 adult patients who received an ASCT in Argentina (10/2002-06/2017) for multiple myeloma or lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.028DOI Listing

Fludarabine, Campath and Low dose Cyclophosphamide (FCC) with or without TBI Conditioning Results in Excellent Transplant Outcomes in Children with Severe Aplastic Anemia.

Biol Blood Marrow Transplant 2020 Jul 5. Epub 2020 Jul 5.

Section of Oncology and BMT, Alberta 'Children's Hospital, University of Calgary, AB Canada.

Various reduced-intensity conditioning regimens are in use for allogeneic hematopoietic cell transplant (HSCT) in idiopathic severe aplastic anemia (SAA). We describe the use of fludarabine, Campath and low dose cyclophosphamide (FCC) conditioning in 15 children undergoing related or unrelated donor transplants. Total body irradiation (TBI) of 2Gy was added for unrelated donor HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.027DOI Listing

Outcomes of haploidentical stem cell transplantation using total body irradiation (600 cGy) and fludarabine with ATG in adult patients with severe aplastic anemia: A prospective phase II study.

Biol Blood Marrow Transplant 2020 Jul 4. Epub 2020 Jul 4.

Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Electronic address:

The aim of this study is to verify the feasibility of rabbit ATG (Thymoglobulin®) (5 mg/kg) in combination with 600 cGy fractionated total body irradiation (fTBI; 200cGy, 3 times) and fludarabine (Flu, 150 mg/m) as a conditioning regimen for haploidentical stem cell transplantation from a related mismatched donor (Haplo-SCT) in adult patients with severe aplastic anemia (SAA). We analyzed 47 consecutive patients who underwent Haplo-SCT, including 24 patients from our previous pilot report. The median age was 36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.024DOI Listing

Low Non-Relapse Mortality after HLA Matched Related Two-Step Hematopoietic Stem Cell Transplantation using Cyclophosphamide (CY) for Graft versus Host Disease Prophylaxis and the Potential Impact of Non-CY-Exposed T Cells on Outcomes.

Biol Blood Marrow Transplant 2020 Jul 3. Epub 2020 Jul 3.

Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University.

The use of cyclophosphamide (CY) for bidirectional tolerization of recipient and donor T cells is associated with reduced rates of graft versus host disease (GVHD) and non-relapse mortality (NRM) after human leukocyte antigen (HLA) matched hematopoietic stem cell transplantation (HSCT). However, recurrent disease remains the primary barrier to long term survival. We extended our two-step approach to HLA matched related HSCT using a radiation-based myeloablative conditioning regimen combined with a high dose of T cells in an attempt to reduce relapse rates while maintaining the beneficial effects of CY tolerization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.021DOI Listing

Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?

Biol Blood Marrow Transplant 2020 Jul 2. Epub 2020 Jul 2.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address:

Immune effector cell (IEC) therapy is emerging as a promising approach in the field of cancer immunotherapy. Clinical IEC trials, predominantly using chimeric antigen receptor (CAR) T cells, have shown excellent responses in CD19 positive B cell malignancies and multiple myeloma. In solid tumors, preclinical data are encouraging, but clinical data are in their infancy, and there are challenges in using CAR T therapy in this setting, including i) on-target off-tumor toxicity, ii) optimal target identification, iii) effective trafficking into bulky tumor tissue, and iv) resistance to tumor immune evasion mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.020DOI Listing

Investigation and management of bone mineral density following HCT: a survey of current practice by the Transplant Complications Working party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant 2020 Jul 2. Epub 2020 Jul 2.

Department of Hematology, University hospital Puerta de Hierro, Madrid, Spain.

Reduced bone mineral density (BMD) is a well recognised complication of haematopoietic cell transplantation (HCT) with significant falls in BMD occurring within the first 12 months of HCT. Guidance on identifying and managing this complication is available in several published guidelines. In this study we have sought to investigate current practise in the investigation and management of low BMD in centres registered with the European Society for Blood and Marrow Transplantation (EBMT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.022DOI Listing

Volume of gadolinium enhancement and successful repair of the blood brain barrier in cerebral adrenoleukodystrophy.

Biol Blood Marrow Transplant 2020 Jun 26. Epub 2020 Jun 26.

Department of Diagnostic Radiology, University of Minnesota Medical Center, Minneapolis, MN.

Up to 40% of boys with adrenoleukodystrophy develop a severe central nervous system demyelinating form (cALD) characterized by white matter changes and gadolinium enhancement on MRI. Hematopoietic cell transplant (HCT) is the only proven means to attenuate cALD progression. The elimination of active neuroinflammation is indicated radiographically by the resolution of gadolinium (Gd) enhancement, and correlates to speed of donor neutrophil recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.019DOI Listing

Who enrolls in an online cancer survivorship program? Reach of the INSPIRE randomized controlled trial for hematopoietic cell transplantation survivors.

Biol Blood Marrow Transplant 2020 Jun 26. Epub 2020 Jun 26.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington School of Medicine, Seattle, WA.

Background: The internet can be a valuable tool in delivering survivorship care to hematopoietic cell transplantation (HCT) cancer survivors. We describe the reach of INSPIRE, an internet and social media-based randomized controlled trial, to address healthcare and psychosocial needs of HCT survivors.

Materials And Methods: All survivors 2-10 years after HCT for hematologic malignancy or myelodysplasia from six transplant centers in the US were approached by mail and follow-up calls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.017DOI Listing

Guidelines for Cord Blood Unit Thaw and Infusion.

Biol Blood Marrow Transplant 2020 Jun 26. Epub 2020 Jun 26.

Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.018DOI Listing

Imaging in Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.

Biol Blood Marrow Transplant 2020 Jun 25. Epub 2020 Jun 25.

Department of Hematology, Institut Gustave Roussy, Villejuif, France.

Veno-occlusive disease/sinusoidal obstruction syndrome is a potentially life-threatening complication of hematopoietic cell transplantation. Early diagnosis and, subsequently, earlier intervention have been shown to be beneficial to clinical outcomes. Diagnostic criteria from the European Society for Blood and Marrow Transplantation include recommendations on the use of imaging for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.016DOI Listing

Global Metabolomics in Allogeneic Hematopoietic Cell Transplant Recipients Discordant for Chronic Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

College of Nursing, University of Florida, Gainesville, Florida, USA.

Background: Chronic graft-versus-host disease (cGVHD) remains a significant late effect issue for allogeneic hematopoietic cell transplantation survivors contributing to morbidity and mortality. The etiology of cGVHD is not well elucidated. Due to lack of early diagnostic tests and pathophysiology ambiguity, there remain limited targeted treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.014DOI Listing
June 2020
3.404 Impact Factor

Splenomegaly May Increase the Risk of Rejection in Low-Risk Matched Related Donor Transplant for Thalassemia, Which Can Be Partially Overcome by Additional Immunosuppression during Conditioning.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

People Tree Hospitals, Bangalore, India; Sankalp India Foundation, Bangalore, India; Cure2Children Foundation, Florence, Italy.

Severe thalassemia syndromes (ST) are highly curable by bone marrow transplant (BMT), but rejection may still occur. We retrospectively analyzed our fully matched related donor transplants to establish if isolated splenomegaly is an independent risk factor for rejection and if this risk can be reduced by modifying the conditioning protocol. In this study, we compared rejection rates between patients with and without splenomegaly in 189 consecutive low-risk ST transplants across 2 sequential conditioning regimens: regimen A (August 2013 and December 2016), including busulfan (14 mg/kg oral, not adjusted to serum levels), cyclophosphamide (200 mg/kg), and anti-thymocyte globulin (ATG) (Genzyme 4 mg/kg or Fresenius 16 mg/kg on days -12 to -10), and regimen B, including the same backbone as regimen A except fludarabine total dose of 150 mg was added upfront and ATG dose was increased to 7 mg/kg in case of splenomegaly and/or sex-mismatched transplants (January 2017 to September 2018). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.013DOI Listing

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address:

Background: Immune checkpoint inhibitors (ICIs) are approved in relapsed classic Hodgkin lymphoma (cHL). The safety and effectiveness of allogeneic blood or marrow transplantation (alloBMT) in ICI pre-treated cHL patients remain unclear. The aim of this study is to assess outcomes of cHL patients receiving ICIs before alloBMT using post-transplantation cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.012DOI Listing

Caregivers' Out-of-Pocket Expenses and Time Commitment Following Hematopoietic Stem Cell Transplantation at a Rural Cancer Center.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

Blood and Marrow Transplant Program.

The emotional and physical toll of cancer patients' caregivers is well characterized, but research evaluating the financial burdens and time commitments of caregivers is limited. We suspected that the rural location of our cancer center would intensify these burdens for caregivers. We conducted a prospective trial to assess the out-of-pocket expenses and time commitment of caregivers of hematopoietic stem cell transplant recipients, within the first four weeks after discharge from the hospital from a National Cancer Institute (NCI) - designated comprehensive cancer center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.015DOI Listing

Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation".

Biol Blood Marrow Transplant 2020 Jun 23. Epub 2020 Jun 23.

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309826PMC

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Biol Blood Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

Roswell Park Comprehensive Cancer Center, Buffalo, New York.

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma." This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.011DOI Listing

Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.

Biol Blood Marrow Transplant 2020 Jun 17. Epub 2020 Jun 17.

BMT & Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Center of International Blood and Marrow Transplant Research, Milwaukee, Wisconsin; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

An increased risk of infections has been described after T cell-replete haploidentical cell transplantation (haploHCT). Cytokine release syndrome (CRS) after haploHCT is a known phenomenon, but the impact of CRS severity on the risk of infections remains unexplored. We retrospectively evaluated 78 consecutive adult haploHCT recipients from 2012 to 2018 for the development of CRS (graded based on the criteria of Lee et al) and examined the incidence and mortality due to infections in correlation with CRS severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.006DOI Listing

Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Biol Blood Marrow Transplant 2020 Jun 16. Epub 2020 Jun 16.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

Allogeneic hematopoietic stem cell transplantation remains an important treatment modality for patients with acute myeloid leukemia (AML). Recent advances have extended donor availability for patients without matched donors. Transplantation is now increasingly offered to older patients, including those above 70 years and less fit individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.007DOI Listing

Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment.

Biol Blood Marrow Transplant 2020 Jun 17. Epub 2020 Jun 17.

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

The integration of antithymocyte globulin (ATG) into therapy has significantly reduced the incidence of graft-versus-host disease (GVHD) and is being actively used in allogeneic hematopoietic stem cell transplantation (allo-HSCT). The ATG dosage is determined by the recipient's body weight, but some insist that this approach does not reflect the actual target of ATG. In this respect, weight-based dosing may lead to ATG overdose, particularly in recipients with a relatively low absolute lymphocyte count (ALC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.005DOI Listing

The SARS-Cov-2 Pandemic: A Good Time for Stem Cell Transplantation?

Biol Blood Marrow Transplant 2020 Jun 16. Epub 2020 Jun 16.

Université Clermont Auvergne, CNRS, INSERM, GReD, Translational Approach to Epithelial Injury and Repair, CHU Clermont-Ferrand, University Hospital of Clermont-Ferrand, Ophthalmology, F-63000 Clermont-Ferrand, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297160PMC
June 2020
3.404 Impact Factor

Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.

Biol Blood Marrow Transplant 2020 Jun 17. Epub 2020 Jun 17.

Moffitt Cancer Center, Tampa, Florida.

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are autologous anti-CD19 chimeric antigen receptor T (CAR T) cell therapies for the treatment of patients with relapsed/refractory large B cell lymphoma (RR-LBCL). Both can induce durable responses; however, cross-trial comparisons are difficult due to differences in study design. In this study, the registration trials of axi-cel and tisa-cel were compared using a matching adjusted indirect comparison (MAIC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.008DOI Listing

Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2020 Jun 11. Epub 2020 Jun 11.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.

The negative impact of iron overload (IO) on outcomes of allogeneic hematopoietic cell transplantation (HCT) is well recognized, but its impact on umbilical cord blood (UCB) transplant outcome is unknown. We retrospectively analyzed outcomes of 150 patients who received UCB-HCT at our institution, stratified by pre-HCT serum ferritin (SF) level of 2000 ng/mL. Two-year overall survival rate among patients with SF >2000 and ≤2000 ng/mL was 26. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.002DOI Listing

Suppression of Hematopoietic Primitive Cells in Patients with Secondary Failure of Platelet Recovery after Acute Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2020 Jun 11. Epub 2020 Jun 11.

Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China. Electronic address:

Secondary failure of platelet recovery (SFPR) can occur after allogeneic hematopoietic stem cell transplantation (alloHSCT), and 20% of cases are related to acute graft-versus-host disease (aGVHD). The underlying mechanisms of this association are unclear, however. The aim of the present study was to investigate the potential mechanisms of SFPR secondary to aGVHD, which may provide a new therapeutic strategy for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.003DOI Listing

Reduced Toxicity Conditioning for Nonmalignant Hematopoietic Cell Transplants.

Biol Blood Marrow Transplant 2020 Jun 11. Epub 2020 Jun 11.

Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, Benioff Children's Hospital, San Francisco, California. Electronic address:

Allogeneic hematopoietic cell transplantation (HCT) for children with nonmalignant disorders is challenged by potential drug-related toxicities and poor engraftment. This retrospective analysis expands on our single pediatric medical center experience with targeted busulfan, fludarabine, and intravenous (IV) alemtuzumab as a low-toxicity regimen to achieve sustained donor engraftment. Sixty-two patients received this regimen for their first HCT for a nonmalignant disorder between 2004 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.06.004DOI Listing

Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: Multicenter Analysis by the Polish Adult Leukemia Group.

Biol Blood Marrow Transplant 2020 Jun 6. Epub 2020 Jun 6.

Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the sole potential cure for paroxysmal nocturnal hemoglobinuria (PNH); however, the data on its utility in PNH are limited. This retrospective analysis of patients with PNH who underwent allo-HSCT in 11 Polish centers between 2002 and 2016 comprised 78 patients with PHN, including 27 with classic PNH (cPNH) and 51 with bone marrow failure-associated PNH (BMF/PNH). The cohort was 59% male, with a median age of 29 years (range, 12 to 65 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.024DOI Listing

Improving Oral Health and Modulating the Oral Microbiome to Reduce Bloodstream Infections from Oral Organisms in Pediatric and Young Adult Hematopoietic Stem Cell Transplantation Recipients: A Randomized Controlled Trial.

Biol Blood Marrow Transplant 2020 Jun 4. Epub 2020 Jun 4.

Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Bloodstream infections (BSIs) from oral organisms are a significant cause of morbidity and mortality in hematopoietic stem cell transplantation (HSCT) recipients. There are no proven strategies to decrease BSIs from oral organisms. The aim of this study was to evaluate the impact of daily xylitol wipes in improving oral health, decreasing BSI from oral organisms, and modulating the oral microbiome in pediatric HSCT recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.019DOI Listing

A Prospective Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplantation Patients.

Biol Blood Marrow Transplant 2020 Jun 4. Epub 2020 Jun 4.

Department of Pharmacy Services, Mayo Clinic Hospital, Rochester, Minnesota. Electronic address:

Limited data exist regarding the prevalence and outcome of medication nonadherence in the adult allogeneic hematopoietic stem cell transplantation (allo-HSCT) population. The objective of this cross-sectional survey study is to determine the prevalence of medication nonadherence to immunosuppressant and nonimmunosuppressant medications in adult recipients of allo-HSCT. An electronic survey using previously validated medication adherence scales was distributed between December 2014 and April 2015 to 200 adult patients with at least 3 months of follow-up after allo-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.020DOI Listing

Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation.

Biol Blood Marrow Transplant 2020 Jun 4. Epub 2020 Jun 4.

Department of Hematology, Toranomon Hospital, Tokyo, Japan; Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Delayed neutrophil engraftment (NE) has been reported in cord blood transplantation (CBT) compared with other stem cell transplantation methods. The numbers of total nucleated cells (TNCs), CD34 cells (generally ≥ 1 × 10/kg), and granulocyte/macrophage colony-forming units (CFU-GM) significantly impact NE. Splenomegaly exerts negative effects on NE, but the appropriate cell dose for the patients with splenomegaly has not yet been determined, especially in CBT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.018DOI Listing

A Case Series of Post-Transplantation Cyclophosphamide in Unrelated Donor Hematopoietic Cell Transplantation for Aplastic Anemia.

Biol Blood Marrow Transplant 2020 Jun 3. Epub 2020 Jun 3.

Universidade Federal do Paraná, Transplante de Medula Ossea, Curitiba, PR, Brazil.

Patients with severe aplastic anemia (SAA) who fail immunosuppressive therapy have a dismal prognosis. Hematopoietic stem cell transplantation (HSCT) from an unrelated donor (URD) is one of the most effective treatment options. Two institutions have independently adopted a post-transplantation cyclophosphamide (PTCy) approach for patients with SAA undergoing HSCT from a URD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.023DOI Listing

Comparative Study of Mizoribine and Mycophenolate Mofetil Combined with a Calcineurin Inhibitor-Based Immunosuppressive Regimen in Patients with Alternative Donor Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2020 Jun 3. Epub 2020 Jun 3.

Transplantation Center or Anemia Disease Center, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. Electronic address:

Cytomegalovirus (CMV) infection and graft-versus-host disease (GVHD) remain the major causes of nonrelapse mortality (NRM) in patients following alternative donor hematopoietic stem cell transplantation (HCT). Mizoribine (MZR) showed an anti-CMV effect in addition to its immunosuppressive effect in patients with renal transplantation. In this study, we aimed to evaluate the efficacy and safety of MZR combined with a calcineurin inhibitor (CNI) as a method of prophylactic immunosuppression in recipients following alternative donor HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.022DOI Listing
June 2020
3.404 Impact Factor

Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.

Biol Blood Marrow Transplant 2020 Jun 3. Epub 2020 Jun 3.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Collaborative Innovation Center of Hematology, Peking University, Beijing, China. Electronic address:

The specific description, risk factors, and outcomes of chronic graft-versus-host disease (cGVHD) in pediatric patients with hematologic malignancies after T cell-replete (TCR) myeloablative haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with antithymocyte globulin (ATG)/granulocyte colony-stimulating factor (G-CSF) have not been previously well described. We retrospectively analyzed the incidence, risk factors, and outcomes of cGVHD documented according to the 2014 National Institutes of Health consensus criteria (NIH-CC) in 292 consecutive pediatric patients with hematologic malignancies after TCR myeloablative haplo-HSCT with ATG/G-CSF between January 2015 and December 2017. A total of 170 patients experienced cGVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.021DOI Listing

Ixazomib for Treatment of Refractory Chronic Graft- versus-Host Disease: A Chronic GVHD Consortium Phase II Trial.

Biol Blood Marrow Transplant 2020 May 25. Epub 2020 May 25.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

New interventions are needed in advanced chronic graft-versus-host disease (GVHD). In a phase II, single-arm, multicenter trial, we examined the efficacy of ixazomib in patients with chronic GVHD who had progressed after at least 1 previous line of systemic immunosuppressive (IS) therapy. Ixazomib was given as a 4 mg oral dose weekly on days 1, 8, and 15 of a 28-day cycle for up to 6 total cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.015DOI Listing

The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.

Biol Blood Marrow Transplant 2020 May 25. Epub 2020 May 25.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Allogeneic hematopoietic stem cell transplantation (alloHCT) may be associated with significant morbidity and mortality, resulting in increased healthcare utilization (HCU). To date, no multicenter comparative cost analyses have specifically evaluated alloHCT in children with acute leukemia. In this retrospective cohort study, we examined the relationship between survival and HCU while investigating the hypothesis that matched sibling donor (MSD) alloHCT has significantly lower inpatient HCU with unrelated donor (URD) alloHCT, and that among URDs, umbilical cord blood (UCB) alloHCT will have higher initial utilization but lower long-term utilization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.016DOI Listing

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant 2020 May 23. Epub 2020 May 23.

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

To date, there are no data focusing on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). This study aimed to evaluate outcomes and prognostic factors in patients with MDS/MPN-U after allo-HSCT using Japanese nationwide registry data. The primary endpoint was 3-year overall survival (OS); secondary endpoints included the cumulative incidence of relapse and nonrelapse mortality (NRM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.013DOI Listing

Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease.

Biol Blood Marrow Transplant 2020 May 25. Epub 2020 May 25.

Service d'Hématologie-greffe, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, INSERM U976, Paris, France. Electronic address:

Almost one-half of patients developing graft-versus-host disease (GVHD) will not respond to standard first-line steroid treatment. Alpha-1 antitrypsin (AAT) is able to induce tolerance in preclinical models of GVHD. AAT alters the cytokine milieu, promotes a tolerogenic shift of dendritic cells, and skews effector T cells toward regulatory T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.014DOI Listing
May 2020
3.404 Impact Factor

Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function.

Biol Blood Marrow Transplant 2020 May 23. Epub 2020 May 23.

Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina. Electronic address:

Despite a well-established risk of chronic kidney disease (CKD) after allogeneic hematopoietic cell transplant (allo-HCT), the benefits of using nephrotoxic anti-infective agents to treat serious peritransplant infections often outweigh this risk. While there is no consensus on the optimal management of post-allo-HCT human herpes virus 6 (HHV6) reactivation, the nephrotoxic drug foscarnet is often used, although its long-term impact on renal function has not been established. We retrospectively reviewed 987 adult patients who underwent transplantation between 2002 and 2016, of whom 45. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.05.007DOI Listing